Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Archives of Neurology

• Publication date

  2005-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHNEUR.62.6.889PMID 15956159
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Type 2 Monocyte and Microglia Differentiation Mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis1

  2004cited by this paper
• Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells1

  2003cited by this paper
• Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor.

  2003cited by this paper
• Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype.

  2003cited by this paper
• Potential of β2-Adrenoceptor Agonists as Add-On Therapy for Multiple Sclerosis

  2002cited by this paper
• The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

  2002cited by this paper
• Effect of combined IFNb-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis

  2002cited by this paper
• Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.

  2002cited by this paper
• Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.

  2002cited by this paper
• Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol).

  2002cited by this paper
• Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

  2002cited by this paper
• Chemokine receptor expression on MBP-reactive T cells: CXCR6 is a marker of IFNgamma-producing effector cells.

  2002cited by this paper
• The effect of IFNβ-1b on the evolution of enhancing lesions in secondary progressive MS

  2001cited by this paper
• European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

  2001cited by this paper
• Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

  2000cited by this paper
• Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1.

  2000cited by this paper
• Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

  2000cited by this paper
• Differential expression of B7 co-stimulatory molecules by astrocytes correlates with T cell activation and cytokine production.

  1999cited by this paper
• Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

  1999cited by this paper
• Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

  1999cited by this paper
• Bystander suppression in experimental autoimmune encephalomyelitis: where and how does it occur?

  1998cited by this paper

• Increased Percentage of CD8+CD28− Regulatory T Cells With Fingolimod Therapy in Multiple Sclerosis

  2022cites this paper
• Role of effector T cells in multiple sclerosis

  2020cites this paper
• The Evolving Mechanisms of Action of Glatiramer Acetate.

  2019cites this paper
• of the Voltage-Gated Potassium Channel Characterization of the Functional Properties

  2017cites this paper
• Further understanding of the immunopathology of multiple sclerosis: impact on future treatments

  2016cites this paper
• Mechanisms of Action of Glatiramer Acetate in the Treatment of Multiple Sclerosis

  2016cites this paper
• Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids

  2015cites this paper
• Non-Biological Complex Drugs

  2015cites this paper
• Glatiramer acetate and therapeutic peptide vaccines for multiple sclerosis

  2014cites this paper
• Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis

  2013cites this paper
• Mechanisms of Action for Treatments in Multiple Sclerosis

  2012cites this paper
• Development of Guillain-Barré syndrome in a patient with multiple sclerosis during treatment with glatiramer acetate.

  2012cites this paper
• Glatiramer Acetate in the Treatment of Multiple Sclerosis

  2011cites this paper
• Expression and functional activity of chemokine receptors in glatiramer acetate-specific T cells isolated from multiple sclerosis patient receiving the drug glatiramer acetate.

  2011cites this paper
• Overlapping and distinct mechanisms of action of multiple sclerosis therapies.

  2010cites this paper
• Chemokine Receptors and NeuroAIDS

  2010cites this paper
• HIV Coreceptors and Their Roles in Leukocyte Trafficking During Neuroinflammatory Diseases

  2009cites this paper
• Protective autoimmunity in the nervous system.

  2009cites this paper
• Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury

  2008cites this paper
• Pharmacogenomics of multiple sclerosis: in search for a personalized therapy

  2008cites this paper
• CCR7 expression on peripheral blood lymphocytes is up-regulated following treatment of multiple sclerosis with interferon-beta

  2007cites this paper
• Mechanism of action of glatiramer acetate in treatment of multiple sclerosis

  2007cites this paper
• Characterization of the Functional Properties of the Voltage-Gated Potassium Channel Kv1.3 in Human CD4+ T Lymphocytes1

  2007cites this paper
• Natalizumab in the Treatment of Patients with Multiple Sclerosis

  2007cites this paper
• Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis

  2007cites this paper
• Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis.

  2007influential citation
• Chemokine Receptors as Biomarkers in Multiple Sclerosis

  2006cites this paper
• Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.

  2006cites this paper
• Glatiramer acetate therapy: the plot thickens.

  2005cites this paper
• Increased Percentage of CD8 + CD28

  year unknowncites this paper